Abstract
Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.
MeSH terms
-
Adolescent
-
Adult
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / microbiology
-
Aspergillosis / prevention & control*
-
Aspergillus / drug effects*
-
Caspofungin
-
Chemoprevention
-
Drug Resistance, Fungal*
-
Echinocandins
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Lipopeptides
-
Male
-
Peptides, Cyclic / pharmacology
-
Peptides, Cyclic / therapeutic use*
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use*
-
Transplantation, Homologous / adverse effects
-
Triazoles / pharmacology
-
Triazoles / therapeutic use*
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
Caspofungin
-
Voriconazole